Lineage Cell Therapeutics, Inc.
AMEXLCTX heads into its May 14 earnings report with fresh analyst coverage and a short base that remains stubbornly elevated — a combination that makes the next two weeks worth watching closely. The most notable development this week came from the Street. Canaccord Genuity initiated coverage on April 28 with a Buy rating and a $9.00 price target — a level that implies more than five…
Snapshot as of 11 May 2026
LCTX heads into its May 14 earnings report with fresh analyst coverage and a short base that remains stubbornly elevated — a combination that makes the next two weeks worth watching closely. The most notable…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LCTX — free to start on ORTEX.
Sign up for free →Open LCTX on ORTEX